Life Technologies Corp (LIFE): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Life Technologies ( LIFE) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole was unchanged today. By the end of trading, Life Technologies fell $1.03 (-2%) to $49.43 on average volume. Throughout the day, 1.8 million shares of Life Technologies exchanged hands as compared to its average daily volume of 1.3 million shares. The stock ranged in price between $49.16-$50.21 after having opened the day at $50.21 as compared to the previous trading day's close of $50.46. Other companies within the Health Care sector that declined today were: Ariad Pharmaceuticals ( ARIA), down 20.7%, Lpath ( LPTN), down 18.8%, MEI Pharma ( MEIP), down 18.8%, and Novogen ( NVGN), down 18.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Life Technologies Corporation operates as a global life sciences company. Life Technologies has a market cap of $8.76 billion and is part of the health services industry. The company has a P/E ratio of 22.2, above the S&P 500 P/E ratio of 17.7. Shares are up 30.8% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Life Technologies a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Life Technologies as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Cardiome Pharma Corporation ( CRME), up 32.8%, Alimera ( ALIM), up 29.1%, Stereotaxis ( STXS), up 20%, and Theratechnologies ( THER), up 19.1%, were all gainers within the health care sector with DaVita HealthCare Partners ( DVA) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.

null

More from Markets

Jim Cramer on Intel CEO Brian Krzanich's Resignation: I Wish Him Well

Jim Cramer on Intel CEO Brian Krzanich's Resignation: I Wish Him Well

Jim Cramer: Disney Has Much More Staying Power Worldwide Than Netflix

Jim Cramer: Disney Has Much More Staying Power Worldwide Than Netflix

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data